Evidence map›Paper›PMID 40950359›Full record

ArticleJournal of gastrointestinal oncology2025

Proximal

Alexander Troester, Claire Sokas, Jack M Wolf, Kyle Rudser, Timothy R Church, Aasma Shaukat, Paolo Goffredo

Abstract read
In one paragraph

Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alexander Troester *Department of Surgery, University of Minnesota, Minneapolis, MN, USA.ORCID https://orcid.org/0000-0001-9182-5814
Claire Sokas *Division of Colon & Rectal Surgery, Department of Surgery, University of Minnesota, Minneapolis, MN, USA.
Jack M WolfDivision of Biostatistics & Health Data Science, University of Minnesota, Minneapolis, MN, USA.ORCID https://orcid.org/0000-0002-8919-8740
Kyle RudserDivision of Biostatistics & Health Data Science, University of Minnesota, Minneapolis, MN, USA.ORCID https://orcid.org/0000-0001-9968-0090
Timothy R ChurchDivision of Environmental Health Sciences, University of Minnesota, Minneapolis, MN, USA.ORCID https://orcid.org/0000-0003-3292-5035
Aasma ShaukatDivision of Environmental Health Sciences, University of Minnesota, Minneapolis, MN, USA.ORCID https://orcid.org/0000-0003-2446-8858
Paolo GoffredoDivision of Colon & Rectal Surgery, Department of Surgery, University of Minnesota, Minneapolis, MN, USA.ORCID https://orcid.org/0000-0001-7078-6625

Funding

University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UM1TR004405 · NCATS · UNIVERSITY OF MINNESOTA · PI Bruce R Blazar, Damien A Fair · 2023 to 2026
$30.8M
NCATS NIH HHS UM1 TR004405
6 · The paper itself

Abstract

Background: Several patient and tumor characteristics impact the prognosis of non-metastatic colon cancer. Among those, tumor location is believed to be a significant factor, as proximal lesions are associated with lower overall survival (OS) in modern cohorts. We aimed to validate these findings in a cohort of patients from the Minnesota Colon Cancer Control Study who underwent curative colectomy. Methods: From 1976 to 1992, 46,551 patients aged 50-80 years were randomized to usual care, annual, or biennial screening with fecal occult blood testing (FOBT). Positive FOBT was followed by colonoscopy. We analyzed participants whose colonoscopy revealed colon adenocarcinoma to estimate the impact of tumor laterality on survival after adjustment for demographic and clinicopathologic characteristics. Proximal tumors were defined as those between the cecum and the splenic flexure. Results: Of 1,486 patients, 796 met inclusion criteria; 57% had proximal cancers. After adjustment, there was no significant difference between proximal and distal tumors in disease-specific mortality [subdistribution hazard ratio (SHR) =0.94, 95% confidence interval (CI): 0.70-1.3], but proximal tumors had lower rates of death from any cause [hazard ratio (HR) =0.9, 95% CI: 0.77-1.00]. Conclusions: Although lacking granular data, these findings from the pre-modern chemotherapy era raise questions about the generalizability of the association between side of origin and prognosis identified in contemporary, treatment-based trials.

Indexed as

Colon cancerdistallateralityoverall survival (OS)proximal

Identifiers

PMID40950359
PMCPMC12432957

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.